Citi: Raises WuXi AppTec (02359) target price to HK$240, maintains "Buy" rating
WuXi AppTec raises its FY2026 total revenue guidance to RMB61.0 billion to RMB61.9 billion, and upgrades its expected year-on-year revenue growth for continuing operations from 35% to 39% to 40% to 42%.
Citi issued a research report stating that it has raised WuXi AppTec's (02359) revenue forecasts for 2026 to 2028 by 2%, 8%, and 11% respectively, and its earnings per share forecasts by 10%, 5%, and 9% respectively; the target price has been raised from HK$215 to HK$240, maintaining a "Buy" rating.
WuXi AppTec's management has raised its FY2026 guidance, with total revenue expected to increase from the previous RMB58.5 billion to RMB60.5 billion to RMB61 billion to RMB61.9 billion; revenue from continuing operations is expected to grow 40% to 42% year-on-year, compared with 35% to 39% previously. In addition, despite facing increased new capacity and foreign exchange headwinds, the company still maintains that its adjusted non-IFRS net profit margin will remain stable and resilient this year.
Related Articles

Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.
MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.

KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.
Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.

MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.
KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.






